Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients

Pfizer Inc. announced positive topline results from the Phase 2 FOURLIGHT-1 study, which showed significant improvement in progression-free survival for 264 patients with HR-positive, HER2-negative advanced breast cancer treated with atirmociclib. The overall survival data is still maturing, with 20% of participants having experienced an event. Additionally, Pfizer received full FDA approval for Braftovi in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation. Following these announcements, Pfizer's stock rose by 1.35% to $26.97.